Frontiers in neurology · 2025
Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Min, Bi Zhuajin, Kang Wenzhong, Liu Ruihan, Hongbo Liu, Jiang Yan, Wang Qun
Аннотация
INTRODUCTION: Temporal lobe epilepsy (TLE) is a significant clinical phenotype of anti-glutamic acid decarboxylase (GAD)-associated disease, which is characterized by disturbances in GABAergic inhibitory neurotransmission. Efgartigimod, a neonatal crystallizable fragment receptor antagonist, controls the trafficking and recycling of pathogenic anti-GAD immunoglobulin G, showing promise as a therapeutic target.
METHODS: We present a case report involving the treatment of three patients affected by GAD-seropositive autoimmune encephalitis with efgartigimod. The patients' overall disability was assessed using the modified Rankin scale.
RESULTS: After 4 weeks of efgartigimod treatment, the patients demonstrated substantial improvements, including no dementia or behavioral abnormalities and well-controlled seizures.
DISCUSSION: Our findings suggest that efgartigimod is a potential candidate drug for the treatment of anti-GADassociated autoimmune encephalitis, particularly in patients presenting with TLE.
METHODS: We present a case report involving the treatment of three patients affected by GAD-seropositive autoimmune encephalitis with efgartigimod. The patients' overall disability was assessed using the modified Rankin scale.
RESULTS: After 4 weeks of efgartigimod treatment, the patients demonstrated substantial improvements, including no dementia or behavioral abnormalities and well-controlled seizures.
DISCUSSION: Our findings suggest that efgartigimod is a potential candidate drug for the treatment of anti-GADassociated autoimmune encephalitis, particularly in patients presenting with TLE.